Ser737
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser737  -  SSFA2 (human)

Site Information
AGyPLRRsQsLPttL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 484807
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 )
Disease tissue studied:
breast cancer ( 4 , 17 ) , breast ductal carcinoma ( 4 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 4 ) , cervical cancer ( 28 ) , cervical adenocarcinoma ( 28 ) , gastric cancer ( 22 ) , gastric carcinoma ( 22 ) , leukemia ( 20 ) , acute myelogenous leukemia ( 20 ) , hepatocellular carcinoma, surrounding tissue ( 27 ) , lung cancer ( 3 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 17 , 25 , 26 ) , non-small cell lung cancer ( 7 , 8 , 9 , 11 , 12 , 17 , 25 , 26 ) , non-small cell lung adenocarcinoma ( 3 , 7 , 8 , 9 , 10 , 11 , 12 , 13 ) , non-small cell large cell lung carcinoma ( 8 , 11 ) , non-small cell squamous cell lung carcinoma ( 10 ) , ovarian cancer ( 4 ) , pancreatic ductal adenocarcinoma ( 6 )
Relevant cell line - cell type - tissue:
'pancreatic, ductal'-pancreas ( 6 ) , 293 (epithelial) ( 21 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 24 ) , A549 (pulmonary) ( 7 , 14 ) , breast ( 1 , 4 ) , BT-20 (breast cell) ( 17 ) , BT-549 (breast cell) ( 17 ) , Cal-12T (pulmonary) ( 12 ) , Calu 6 (pulmonary) ( 17 ) , Calu-3 (pulmonary) ( 9 ) , Flp-In T-Rex-293 (epithelial) ( 18 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 18 ) , H2009 (pulmonary) ( 17 ) , H2077 (pulmonary) ( 17 ) , H2887 (pulmonary) ( 17 ) , H322 (pulmonary) ( 17 ) , H322M (pulmonary) ( 17 ) , HCC1359 (pulmonary) ( 17 ) , HCC15 (pulmonary) ( 10 ) , HCC1937 (breast cell) ( 17 ) , HCC2279 (pulmonary) ( 17 ) , HCC366 (pulmonary) ( 17 ) , HCC4006 (pulmonary) ( 17 ) , HCC44 (pulmonary) ( 12 ) , HCC78 (pulmonary) ( 11 , 17 ) , HCC827 (pulmonary) ( 9 , 17 ) , HeLa (cervical) ( 16 , 23 , 31 , 32 ) , HeLa S3 (cervical) ( 28 ) , hepatocyte-liver ( 27 ) , HOP62 (pulmonary) ( 17 ) , Jurkat (T lymphocyte) ( 15 ) , K562 (erythroid) ( 16 , 29 ) , KG-1 (myeloid) ( 20 ) , LCLC-103H (pulmonary) ( 17 ) , liver ( 5 ) , LOU-NH91 (squamous) ( 10 , 17 ) , lung ( 7 , 8 , 9 , 10 , 11 , 12 , 13 ) , MCF-7 (breast cell) ( 17 ) , MDA-MB-231 (breast cell) ( 17 ) , MDA-MB-468 (breast cell) ( 17 ) , MKN-45 (gastric) ( 22 ) , NCI-H1299 (pulmonary) ( 8 ) , NCI-H1355 (pulmonary) ( 7 ) , NCI-H1395 (pulmonary) ( 17 ) , NCI-H1437 (pulmonary) ( 12 ) , NCI-H1568 (pulmonary) ( 17 ) , NCI-H157 (pulmonary) ( 17 ) , NCI-H1648 (pulmonary) ( 17 ) , NCI-H1650 (pulmonary) ( 9 , 25 , 26 , 30 ) , NCI-H1666 (pulmonary) ( 12 , 17 ) , NCI-H1703 (squamous) ( 10 ) , NCI-H1734 (pulmonary) ( 8 ) , NCI-H1781 (pulmonary) ( 11 ) , NCI-H1792 (pulmonary) ( 7 ) , NCI-H1944 (pulmonary) ( 8 ) , NCI-H1975 (pulmonary) ( 9 ) , NCI-H2030 (pulmonary) ( 17 ) , NCI-H2073 (pulmonary) ( 10 ) , NCI-H2106 (pulmonary) ( 9 ) , NCI-H2172 (pulmonary) ( 17 ) , NCI-H2228 (pulmonary) ( 11 ) , NCI-H23 (pulmonary) ( 7 ) , NCI-H2342 (pulmonary) ( 10 ) , NCI-H2405 (pulmonary) ( 12 ) , NCI-H3122 (pulmonary) ( 11 ) , NCI-H358 (pulmonary) ( 8 ) , NCI-H441 (pulmonary) ( 7 ) , NCI-H460 (pulmonary) ( 8 , 17 ) , NCI-H520 (squamous) ( 17 ) , NCI-H647 (pulmonary) ( 17 ) , NCI-H661 (pulmonary) ( 11 ) , ovary ( 4 ) , PC9 (pulmonary) ( 3 , 17 )

Upstream Regulation
Treatments:
MLN8054 ( 23 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

3

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

4

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

5

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

6

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

10

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

11

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

12

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

13

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

14

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

15

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

16

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

17

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

18

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

19

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

20

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

21

Mulhern D (2011) CST Curation Set: 12831; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

22

Moritz A (2011) CST Curation Set: 11944; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

23

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

24

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

25

Possemato A (2010) CST Curation Set: 9738; Year: 2010; Biosample/Treatment: cell line, H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

26

Possemato A (2010) CST Curation Set: 9732; Year: 2010; Biosample/Treatment: cell line, H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

27

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

28

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

29

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

30

Possemato A (2009) CST Curation Set: 8050; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

31

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

32

McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80
18212344   Curated Info